Announcements

Job Offers

Top 5 -yesterday

Top 5 -last week

Top 5 -last month

EU independent cannabis company raises £15 million

EMMAC Life Sciences Group has raised £15.0 million via an issue of Convertible Loan Notes (the “CLN Issue”). The CLN Issue saw strong support from existing shareholders, with Measure 8 Venture Partners LP, EMMAC’s largest existing cash investor, leading the round with a significant investment.

EMMAC continues to build upon its position as one of Europe’s largest independent cannabis companies and is seeing growth in its key markets in Europe as the demand for premium medical cannabis and wellness products grows. The UK medical cannabis market in particular is witnessing significant momentum, with EMMAC leading the way in enabling greater patient access in terms of product accessibility and cost for patients.

Antonio Costanzo, CEO of EMMAC, said: “We are pleased to see strong interest in this round of funding, which will allow EMMAC to continue to scale and build on its position as the European leader. I would like to take the opportunity to thank Measure 8 for its support leading this funding round and to all shareholders for their support as we grow a robust and sustainable business.”

For more information:
EMMAC Life Science Group
Gilmoora House, 57-61 Mortimer Street, London, W1W 8HS
enquiries@emmac.com 
emmac.com 


Publication date:



Receive the daily newsletter in your email for free | Click here


Other news in this sector:


Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber